LFCR vs SGP
LFCR: Lifecore Biomedical is a specialized CDMO focused on complex sterile injectable fill-finish and manufacturing services for the pharmaceutical industry. SGP: Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
Side-by-side fundamentals
| Metric | LFCR | SGP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.58 | $20.54 | |
| Market cap as of 2026-07-23 | $174M | $682M | |
| Net margin as of 2026-07-23 | -26.5% | n/a | |
| Gross margin as of 2026-07-23 | +30.0% | n/a | |
| Operating margin as of 2026-07-23 | -1.9% | n/a | |
| ROE as of 2026-07-23 | -126.8% | -75.4% | SGP higher |
| ROA as of 2026-07-23 | -18.9% | -68.8% | LFCR higher |
| Debt / equity as of 2026-07-23 | 7.16 | 0.00 | SGP lower |
| Revenue growth (YoY) as of 2026-07-23 | +27.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.3% | n/a | |
| Beta as of 2026-07-23 | 1.12 | 0.97 | |
| 1-year return as of 2026-07-22 close | -38.4% | -23.2% | SGP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.